glp·helper
glphelper.com/mounjaro/wisconsin/milwaukee
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022Rx · Subcutaneous injection · Once weekly

Mounjaro® providers &
prescriptions in Milwaukee, WI

Verified Mounjaro providers in Milwaukee, WI. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Mounjaro weight loss →trial-anchored estimate
city providers
31
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Wisconsin
31 of 31 shown

Find a Mounjaro provider in Wisconsin.

Every entry is checked against the NPI registry and the Wisconsin medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Wisconsin city · /mounjaro/wisconsin/{city}
§ 03Getting Mounjaro in Milwaukee
31 providers · Milwaukee, WI

How to get Mounjaro in Milwaukee.

31 GLP-1 prescribers and 7 local resource types are on record for Milwaukee, plus 2 nearby towns in the directory.

Prescribers in Milwaukee
31 prescribers
31 GLP-1 prescribers in Milwaukee, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (14), Family Medicine (14) and Internal Medicine (2). Any Wisconsin-licensed physician, nurse practitioner, or PA can prescribe Mounjaro, over video or in person. The nearest towns on record are Madison (38 providers) and Green Bay (31 providers).
Around the prescription in Milwaukee
7 listed nearby
6 dietitians, 6 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Milwaukee.
Medicaid (weight loss)
Covered
As of April 2026, Wisconsin Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Wisconsin’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes. Same molecule as Zepbound.

Mounjaro is the brand name Eli Lilly uses for tirzepatide approved for type 2 diabetes. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one. The identical molecule, marketed as Zepbound, is the FDA-approved formulation for chronic weight management.[2][3]

In the SURPASS-2 head-to-head trial, tirzepatide produced greater HbA1c reductions and greater weight loss than semaglutide 1 mg across all doses. Across the SURPASS program, tirzepatide lowered HbA1c by approximately 1.8 to 2.6 percentage points. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Zepbound is the FDA-approved tirzepatide for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Wisconsin

Diagnosed diabetes reaches 9.6% of adults in Wisconsin.

of Wisconsin adults have obesity
37.4%
diagnosed diabetes
9.6%

Age-adjusted estimates for Wisconsin, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight losswhat happens after GLP-1s stop
§ 05Support around Mounjaro in Milwaukee
6 dietitians

The prescription is one part. Here is the rest, in Milwaukee.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Milwaukee, WI, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Dipti Adamson, RD, CD
RD
Registered dietitian
2900 W Oklahoma Ave
Call 414-649-7535NPI 1487884219
Natalie Alcaraz, RDN
RD
Registered dietitian
333 W Brown Deer Rd Unit G783
Call 414-640-3118NPI 1184361461
Linda Allen, RD, CD
RD
Registered dietitian
5000 W National Ave
Call 414-384-2000NPI 1114947496
Katie Auble
RD
Registered dietitian
1857 E Kenilworth Pl Apt 203
Call 414-639-5746NPI 1902618002
Carmel Bankier Sweet, RD
RD
Registered dietitian
1020 N 12Th St
Call 414-219-2000NPI 1457427544
Brenna Bartkowicz, RD
RD
Registered dietitian
2801 W Kinnickinnic River Pkwy Ste 260
Call 414-328-7314NPI 1760336085

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Planet Fitness
GYM
4.8 on Google · 1523 reviews
5730 W Capitol Pkwy
Website
Crunch Fitness - Greenfield
GYM
4.7 on Google · 1208 reviews
6251 S 27th St
Website
VASA Fitness
GYM
4.0 on Google · 1064 reviews
13995 W National Ave
Website
Planet Fitness
GYM
4.6 on Google · 1036 reviews
4478 S 108th St
Website
Planet Fitness
GYM
4.5 on Google · 907 reviews
15740 W Capitol Dr
Website
Crunch Fitness - Hales Corners
GYM
4.8 on Google · 843 reviews
5321 S 108th St
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

Across the SURPASS program, tirzepatide reduced HbA1c by approximately 1.8 to 2.6 percentage points and produced substantial weight loss, outperforming insulin and GLP-1 comparators. Mounjaro is approved as an adjunct to diet and exercise for glycemic control in adults with T2D.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Mean weight change (15 mg, obesity)
−20.9%
SURMOUNT-1, 72 wk (Zepbound)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Mounjaro weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Mounjaro cash price (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Mounjaro providers in Wisconsin

NPI-verified Mounjaro (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Mounjaro in other states

Find NPI-verified Mounjaro (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Mounjaro in Wisconsin

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Insurers treat them as separate products, and coverage differs sharply between the two.[1]